The Nano Therapy Market is developing across several therapeutic, technological, and end-user segments. According to WiseGuyReports, the global market was valued at USD 4.4 billion in 2024 and is expected to reach USD 10.5 billion by 2035, growing at an estimated CAGR of 8.1%.

By application, the market includes cancer therapy, cardiovascular therapy, neurological therapy, and infectious disease therapy. Cancer therapy is a leading segment, supported by increasing cancer prevalence and the demand for more targeted treatment approaches. The report indicates that cancer therapy was valued at USD 1.8 billion in 2024 and is projected to reach USD 3.9 billion by 2035.

Product types include nanoparticles, nanocarriers, nanosheets, and nanorobots. End users include hospitals, research institutions, and pharmaceutical companies. Key technologies include targeted drug delivery, diagnostic imaging, and gene therapy.

Major companies profiled in the market include Eli Lilly and Company, AstraZeneca, Johnson & Johnson, Amgen, Pfizer, Roche, Novartis, Sanofi, Thermo Fisher Scientific, Merck KGaA, and NanoComposix.

The competitive environment is influenced by research investments, technological innovation, partnerships, and the development of advanced nano-based therapeutic products. Continued innovation is expected to strengthen competition and expand market opportunities.